{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Assessment+and+Follow+Up+Evaluation&page=3",
    "query": {
      "intervention": "Safety Assessment and Follow Up Evaluation",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1244,
    "total_pages": 125,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Assessment+and+Follow+Up+Evaluation&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Assessment+and+Follow+Up+Evaluation&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T19:45:58.021Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04393909",
      "title": "Improving Safety of Diagnosis and Therapy in the Inpatient Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Delirium",
        "Confusion",
        "Mental Status Change",
        "Back Pain",
        "Hip Pain Chronic",
        "Chest Pain",
        "Asthma",
        "COPD",
        "Cellulitis",
        "Soft Tissue Infections",
        "Cough",
        "Deep Vein Thrombosis",
        "Pulmonary Embolism",
        "Venous Thromboembolism",
        "Dyspnea",
        "Electrolyte Metabolism Abnormal",
        "Fever",
        "Failure to Thrive",
        "Weakness",
        "Protein-Calorie Malnutrition",
        "Headache",
        "Neck Pain",
        "Hypoxia",
        "Pneumonia",
        "Sepsis",
        "Syncope",
        "Vomiting",
        "Diarrhea",
        "Leg Pain",
        "Abdominal Pain"
      ],
      "interventions": [
        {
          "name": "Diagnostic Uncertainty Educational Curriculum",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Diagnostic Timeout",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient Diagnostic (Dx) Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhancements to Epic-integrated Quality & Safety Dashboard",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2019-07-01",
      "completion_date": "2021-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04393909"
    },
    {
      "nct_id": "NCT03238963",
      "title": "A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "BI 1467335",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 79,
      "start_date": "2017-09-19",
      "completion_date": "2020-05-14",
      "has_results": true,
      "last_update_posted_date": "2021-06-04",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 16,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03238963"
    },
    {
      "nct_id": "NCT03524118",
      "title": "Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Infection",
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Clesrovimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "2 Weeks to 8 Months"
      },
      "enrollment_count": 183,
      "start_date": "2018-09-20",
      "completion_date": "2022-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524118"
    },
    {
      "nct_id": "NCT00336492",
      "title": "A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "infliximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-09",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336492"
    },
    {
      "nct_id": "NCT02521792",
      "title": "In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Palovarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-12-07",
      "completion_date": "2016-08-04",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02521792"
    },
    {
      "nct_id": "NCT05419492",
      "title": "A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "ETX101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Encoded Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 47,
      "start_date": "2024-05-14",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05419492"
    },
    {
      "nct_id": "NCT02562066",
      "title": "Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenic Syndromes, Congenital"
      ],
      "interventions": [
        {
          "name": "amifampridine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-01",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2021-04-02",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02562066"
    },
    {
      "nct_id": "NCT04925713",
      "title": "IFx-Hu2.0 for the Treatment of Patients With Skin Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IFx-Hu2.0",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TuHURA Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-06-10",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 1,
      "location_summary": "Brandon, Florida",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04925713"
    },
    {
      "nct_id": "NCT05362370",
      "title": "Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cranioplasty",
        "Craniofacial Abnormalities",
        "Craniofacial Injuries"
      ],
      "interventions": [
        {
          "name": "Stryker's PEEK Customized Implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stryker Craniomaxillofacial",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "42 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "42 Months and older"
      },
      "enrollment_count": 99,
      "start_date": "2023-02-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 5,
      "location_summary": "Louisville, Kentucky • New Brunswick, New Jersey • New York, New York + 2 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05362370"
    },
    {
      "nct_id": "NCT06224413",
      "title": "A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cerebral Adrenoleukodystrophy (CALD)"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2024-03-27",
      "completion_date": "2047-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-07T19:45:58.021Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06224413"
    }
  ]
}